Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $398,855.04 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Bryan Supran sold 1,758 shares of the firm’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the sale, the executive vice president directly owned 12,807 shares in the company, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock traded up $4.05 during trading hours on Tuesday, hitting $223.94. The company’s stock had a trading volume of 1,353,733 shares, compared to its average volume of 1,449,769. The business has a 50 day moving average price of $240.21 and a two-hundred day moving average price of $279.65. Alnylam Pharmaceuticals, Inc. has a 12-month low of $197.81 and a 12-month high of $495.55. The company has a market cap of $29.97 billion, a PE ratio of 41.62 and a beta of 0.28. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.63 by $0.21. The firm had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm’s revenue was up 66.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.51) earnings per share. Analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.71 earnings per share for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Bank of Nova Scotia lifted its position in shares of Alnylam Pharmaceuticals by 0.6% during the 1st quarter. Bank of Nova Scotia now owns 7,798 shares of the biopharmaceutical company’s stock worth $2,580,000 after buying an additional 49 shares during the last quarter. Prestige Wealth Management Group LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 30.6% in the 1st quarter. Prestige Wealth Management Group LLC now owns 226 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 53 shares in the last quarter. Glenmede Trust Co. NA grew its position in shares of Alnylam Pharmaceuticals by 8.3% in the 1st quarter. Glenmede Trust Co. NA now owns 731 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 56 shares during the last quarter. MV Capital Management Inc. acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $25,000. Finally, Parallel Advisors LLC raised its stake in Alnylam Pharmaceuticals by 7.9% during the 1st quarter. Parallel Advisors LLC now owns 891 shares of the biopharmaceutical company’s stock worth $295,000 after acquiring an additional 65 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ALNY shares. JPMorgan Chase & Co. cut their price objective on shares of Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating for the company in a report on Wednesday, September 30th. Stifel Nicolaus lowered their target price on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Morgan Stanley dropped their target price on shares of Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating for the company in a research report on Friday, July 31st. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 30th. Finally, Royal Bank Of Canada reduced their price target on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $366.90.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis.